- Details
- HPN424 is a prostate-specific membrane antigen (PSMA)-targeting T cell engager designed to redirect T cells to kill PSMA-expressing prostate cancer cells. It is engineered with three binding domains: anti-PSMA for tumor cell engagement, anti-albumin for half-life extension, and anti-CD3 for T cell engagement. Furthermore, HPN424 is optimized for small size and increased stability compared to other...
|
- Details
- In an oral presentation at the 2021 ASCO annual meeting, Andrea Necchi, MD provided a discussion on combination immunotherapy, checkpoint inhibitors, with radiation or chemoradiation approaches to bladder-sparing. In this conversation with Alicia Morgans, MD, MPH, he highlights several abstracts including a US phase II study presented by Arjun Balar of immunotherapy with pembrolizumab combined wit...
|
- Details
- Neoadjuvant cisplatin-based chemotherapy is associated with pathologic complete response (pCR) in muscle-invasive bladder at the time of cystectomy for a proportion of patients with muscle-invasive bladder cancer (MIBC). Patients with a pCR have improved overall survival relative to patients with no pCR. A challenge in the treatment of patients with MIBC is identifying patients that may be able to...
|
- Details
- In this conversation with Alicia Morgans, MD, MPH, Arjun Balar, MD highlights a multicenter study first designed in 2014 of gemcitabine hypofractionated radiation therapy and pembrolizumab all in combination as bladder-sparing therapy for patients with muscle-invasive bladder cancer that had a total of 54 patients. The goal of the study was to test the role of immunotherapy pembrolizumab added to...
|
- Details
- Cisplatin chemotherapy is the standard of care for medically fit patients in advanced urothelial carcinoma. Unfortunately, up to 50% of these patients are medically ineligible for cisplatin due to low-performance status, renal dysfunction, or other medical comorbidities. Immune checkpoint blockade is a first-line therapeutic option in either platinum ineligible patients or carboplatin eligible pat...
|
- Details
- In an educational session at the 2021 ASCO annual meeting titled Beyond the Androgen Receptor: New Avengers in the Treatment of Castrate-Resistant Metastatic Cancer, Mark Fleming, MD presented on treatment sequencing in castrate-resistant metastatic cancer (CRPC). In this conversation with Charles Ryan, MD, he speaks to the complex therapeutic landscape and offers guidance in managing treatment se...
|
- Details
- This conversation with Alicia Morgans, MD, MPH, Petros Grivas, MD, PhD, highlights a post hoc analysis of the JAVELIN Bladder 100 trial which further characterizes the efficacy of avelumab first-line maintenance of time to end of next-line therapy. In JAVELIN Bladder 100, eligible patients had unresectable locally advanced or metastatic urothelial carcinoma without disease progression with 4 to 6...
|
- Details
- In this conversation with Alicia Morgans, MD, MPH, Tian Zhang, MD, highlights a phase II trial lead by Sumanta Kumar (Monty) Pal evaluating the efficacy and safety of cisplatin and gemcitabine hydrochloride with or without berzosertib works in treating patients with urothelial cancer that has metastasized, presented at ASCO 2021. Berzosertib is an ATR inhibitor with preclinical data suggestive of...
|
- Details
- In this conversation with Alicia Morgans, MD, MPH, Siamak (Sia) Daneshmand discusses long-term follow-up of testicular cancer patients, a topic of interest to many navigating testicular cancer survivorship. Dr. Daneshmand provided an oral abstract discussion during the 2021 ASCO annual meeting highlighting two abstracts Testicular Cancer in the Cisplatin Era: Causes of Death and Mortality Rates in...
|
- Details
- Bone strengthening agents such as bisphosphonates or the RANKL-targeting antibody denosumab reduced the bone loss associated with androgen deprivation therapy (ADT) and prevent skeletal-related events in castration resistant prostate cancer (CRPC). The use of these agents is recommended in CRPC by many guidelines. The randomized phase III EORTC-1333-GUCG also known as the PEACE-III trial, compares...
|
